DSM: Q1 2005 Operating Profit EUR 188 Million, Up 44% From Q1 2004


HEERLEN, Netherlands, April 27, 2005 (PRIMEZONE) -- DSM:


 -- Sales up 4% from Q1 2004. 
 -- Operating profit(a) 44% higher than in Q1 2004. 
 -- Net profit from ordinary activities up 35% from Q1 2004. 
 -- NeoResins acquisition completed; integration started. 
 -- Q2 operating profit expected to be higher than in Q1 2005 and 
    substantially above Q2 2004 level (EUR 152 million).

 in EUR million                           first quarter 
                                          2005    2004    +/-
 Net sales                               1,984   1,902     4%
 Operating profit from ordinary 
  activities plus depreciation
  and amortization (EBITDA)                310     250    24%
 Operating profit from ordinary 
  activities (EBIT)                        188     131    44% 

 -- Life Science Products                   24      22     9%
     DSM Nutritional Products               63      46    37%
 -- Performance Materials                   67      42    60%
 -- Industrial Chemicals                    43      24    79%
 -- Other activities                       -10      -5
 -- divested activities of DSM Bakery        1       2
     Ingredients
 Net profit from ordinary activities       131      97    35%
  excluding exceptional items
 Net result from exceptional items          --     -33
 Net profit                                131      64   105%
 Per ordinary share in EUR:
 -- net earnings from ordinary activities 1.33    0.95
 -- net earnings                          1.33    0.61
 Average number of ordinary shares        95.8    95.8
  (x million)

 (a) In this report, 'operating profit' is understood to be operating
     profit from ordinary activities excluding exceptional items.

Q1 2005 operating profit EUR 188 million, up 44% from Q1 2004

General

DSM posted an Operating profit of EUR 188 million in the first quarter of 2005, up EUR 57 million from the first quarter of 2004. Net profit from ordinary activities was EUR 131 million, an increase of 35% compared with Q1 2004. Net profit doubled compared with the first quarter of the previous year, when the net profit was negatively influenced by an exceptional item.

Commenting on the results, Peter Elverding, Chairman of the DSM Managing Board, said: "We are satisfied with the development of our results for the first quarter. Our profitability has clearly improved. We will continue to work hard on innovation and productivity enhancement to further improve our profitability level.

"We managed to consolidate last year's good volume growth and were able to raise prices. What I find particularly favourable is the positive development at Performance Materials, while Industrial Chemicals and DSM Nutritional Products also posted fine results.

"The development of the dollar and the prices of raw materials continue to be uncertain factors in our markets. If market conditions remain at the first-quarter level, the perspectives for DSM's results in 2005 remain positive."

Net sales


  in EUR million                         first quarter 
                                         2005     2004

  Life Science Products                   337      374 
  DSM Nutritional Products                463      471
  Performance Materials                   564      472 
  Industrial Chemicals                    409      364 
  Other activities                        133      131 
  Divested activities of DSM Bakery 
   Ingredients                             78       90

  Total                                 1,984     1,902

Q1 2005 sales increased by more than 4% compared with the first quarter of 2004. Having increased strongly in 2004, sales volumes remained virtually unchanged while prices were clearly higher, leading to a 3% sales increase on balance. DSM NeoResins' contribution to sales (from 2 February onwards) was more than 2%. Exchange rate developments had an effect of -1%.

Operating profit

The operating profit for the first quarter was EUR 188 million, up 44% compared with the first quarter of 2004. DSM Nutritional Products and the Performance Materials and Industrial Chemicals clusters performed clearly better than in the first quarter of 2004.

Business review


 Life Science Products cluster

   in EUR million                                first quarter(b) 
                                                 2005     2004

   Net sales including intra-group supplies       351      402 
   Operating profit plus depreciation and 
    amortization                                   55       59 
   Operating profit                                24       22

 (b) Excluding divested activities of DSM Bakery Ingredients

Sales of this cluster (excluding divested activities) were down 13% from the first quarter of 2004 as sales volumes were lower on balance (due mainly to the closure of the phenol activities in Rotterdam (the Netherlands) and the chemical synthesis activities in Greenville (USA) and to lower volumes at DSM Anti-Infectives) and prices were also lower on balance. DSM Food Specialties saw its sales and operating profit improve considerably, due among other things to higher sales volumes. In the other business groups, the effect of lower sales was to a large extent compensated for by structural cost reductions that had been achieved.

On 13 April, DSM and Gilde Investment Management announced that they had concluded an agreement on DSM's sale of the greater part of the activities of DSM Bakery Ingredients to Gilde. The agreed transaction price is EUR 197.5 million. In this and subsequent quarterly reports, these activities will be presented separately in the results and in the balance sheet. Net sales of these activities in the first quarter of 2005, including intra-group supplies, amounted to EUR 78 million (2004: EUR 92 million), and operating profit plus depreciation and amortization amounted to EUR 5 million (2004: EUR 6 million).


 DSM Nutritional Products

  in EUR million                                 first quarter 
                                                 2005     2004

  Net sales including intra-group supplies        468      471
  Operating profit plus depreciation and 
   amortization                                    92       75
  Operating profit                                 63       46

Sales were stable; the effect of the lower dollar exchange rate and price declines for some products was virtually compensated for by an increase in sales volumes.

In Human Nutrition and Health, volumes were stable at slightly lower prices. The Animal Nutrition and Health business posted higher volumes than last year, when there was an outbreak of avian flue in Asia, but selling prices were under pressure.

The operating profit was substantially higher due to the lower level of fixed and variable costs resulting from the successful implementation of the VITAL integration and transformation project.


 Performance Materials cluster

   in EUR million                                first quarter 
                                                 2005     2004

   Net sales including intra-group supplies       568      477 
   Operating profit plus depreciation and 
    amortization                                   93       62 
   Operating profit                                67       42

Sales were up 19% due to the contribution from DSM NeoResins (+9%, two months) and higher selling prices for all business groups. The operating profit for the cluster improved, mainly due to higher margins. All business groups in the cluster contributed to this performance, with DSM Elastomers and DSM Dyneema in particular showing a strong increase in profits.

DSM NeoResins' sales and EBITDA developed in line with expectations. The integration process got off to an energetic start.


 Industrial Chemicals cluster

    in EUR million                                 first quarter 
                                                   2005     2004

    Net sales including intra-group supplies        458      404
    Operating profit plus depreciation and 
     amortization                                    64       43
    Operating profit                                 43       24

Sales of this cluster on balance increased substantially compared with the first quarter of 2004, due mainly to considerably higher selling prices for caprolactam. DSM Fibre Intermediates recorded a very strong increase in its operating profit compared with Q1 2004, continuing the upward trend of previous quarters. DSM Melamine's results improved compared with the end of 2004 and were comparable to the level of the first quarter of 2004. DSM Agro's operating profit was lower, mainly due to lower margins for ammonia and a shift in volumes due to a late start of the fertilizer application season.


 Other activities

    in EUR million                                 first quarter 
                                                   2005     2004

    Net sales including intra-group supplies        135      131
    Operating profit plus depreciation and 
     amortization                                     1        5
    Operating profit                                -10       -5

The operating profit of the Other activities cluster was lower than in the first quarter of last year due to the costs of a number of projects.

Net profit

Net profit was up EUR 67 million (105%) from Q1 2004 (when the net profit was influenced by an exceptional item) and stood at EUR 131 million.

Net finance costs in the first quarter of 2005 amounted to EUR 12 million, which is EUR 4 million less than in the first quarter of 2004. The decrease was mainly a result of the decrease in interest charges due to a lower level of borrowings and a lower dollar exchange rate.

At 27%, the Effective tax rate in the first quarter of 2005 was higher than in Q1 2004 (22%). This increase was due to a decrease in the proportion of income elements taxed at a low rate.

Net profit from ordinary activities amounted to EUR 131 million, up EUR 34 million (35%) from the first quarter of 2004.

Net earnings per share from ordinary activities available to holders of ordinary shares increased by 40%. This increase is higher than that of the Net profit from ordinary activities because of the buy-back of cumulative preference shares C at the end of 2004 and the associated decrease in the dividend on the cumulative preference shares in 2005.

Balance sheet

The DSM NeoResins acquisition has temporarily been recognized under Financial assets at the acquisition price of EUR 515 million. In the presentation of the figures for the second quarter, DSM NeoResins will be recognized as a consolidated company.

Cash flow, capital expenditure and financing

The cash flow (net profit plus depreciation) in the first quarter amounted to EUR 253 million, an increase of EUR 70 million compared with the first quarter of 2004. At EUR 56 million, capital expenditure (excluding acquisitions) was substantially lower than the level of depreciation (EUR 122 million) and slightly below the level of Q1 2004 (EUR 66 million).

Net debt increased by EUR 675 million in Q1 2005 and stood at EUR 1,016 million. The increase in net debt was due to the acquisition of NeoResins in early February 2005, the increase in working capital and the repurchase of shares to service option rights.

Workforce

The workforce on balance increased by 185 compared with year-end 2004. As a result of the acquisition of NeoResins, the workforce increased by 631. Restructuring measures and attrition were responsible for a decrease of 446, of which 145 at DSM Nutritional Products and 165 in the Life Science Products cluster.

Outlook

Market conditions remained robust in the first quarter of 2005, enabling DSM to raise the prices of a number of its products.

DSM is confirming the indication it gave in February with regard to the year 2005 as a whole. If the business environment continues to develop in line with 2004 and the first quarter of 2005, the prospects for an increase in DSM's financial results are definitely positive. However, European producers may see themselves confronted with the negative effects of a further weakening of the dollar versus the euro. Moreover, the continuing volatility of raw material prices and possible pressure on economic growth in Europe and the USA are risk factors for the chemical industry.

Based on current insights, DSM foresees continuing good market conditions for the second quarter of 2005. The Q2 2005 operating profit is expected to be higher than that for Q1 2005 and thus substantially higher than the Q2 2004 level (EUR 152 million).

Heerlen, 27 April 2005

The Managing Board of Directors

Important dates:


 Publication of second-quarter results:  Wednesday, 27 July 2005 
 Interim dividend 2005:                  Thursday, 11 August 2005 
 Publication of third-quarter results:   Thursday, 27 October 2005 
 Annual report 2005:                     Thursday, 9 February 2006 
 Annual General Meeting:                 Wednesday, 29 March 2006


            

Coordonnées